HEFCE Senior Lecturer; Honorary Consultant in Metabolic Bone Disease and Rheumatology, Department of Medicine
Email:kp254@medschl.cam.ac.uk
Research Interests
I am a University Lecturer and honorary consultant rheumatologist at the University of Cambridge, applying novel imaging techniques to investigate human bone diseases. Research in the bone group focuses on osteoporotic fragility fractures and osteoarthritis by examining bone structure and shape in health and disease. With scientists from the University Engineering for Clinical Practice initiative, we pioneered a way of assessing the 3D structure and shape of cortical bone structure in life called Cortical Bone Mapping (CBM). We have used CBM to discover not only that there are patches of focal osteoporosis in women with hip fracture, but also that various therapies and exercise interventions make the femur cortex thicker in key areas at risk of fracture. We are also interested in histological and high resolution CT analysis of bone, as well as osteocyte signals and their role in skeletal regulation.
Selected publications
Poole KE, Treece GM, Gee AH, Brown JP, McClung MR, Wang A, et al.(2014) Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women with Osteoporosis. J Bone Miner Res. Jan 30(1);46-54
Turmezei TD, Fotiadou A, Lomas DJ, Hopper MA, Poole KE. (2014) A new CT grading system for hip osteoarthritis. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society. Oct 22(10);1360-66
Poole KE, Treece GM, Mayhew PM, Vaculik J, Dungl P, Horak M, et al.(2012) Cortical thickness mapping to identify focal osteoporosis in patients with hip fracture. PloS ONE. 7(6): e38466 http://www.ncbi.nlm.nih.gov/pubmed/22701648
Poole KES, Treece GM, Ridgway GR, Mayhew PM, Borggrefe J, Gee AH. (2011) Targeted Regeneration of Bone in the Osteoporotic Human Femur. PLoS ONE 6:e1619 http://www.ncbi.nlm.nih.gov/pubmed/21264263
Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J.(2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J 19:1842-1844. http://www.ncbi.nlm.nih.gov/pubmed/16123173